Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) released second-quarter results and hosted a quarterly call, where management provided a corporate update as well as an update on clinical …
In a research report issued this morning, Needham analyst Alan Carr weighed in on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), after the drug maker released its second-quarter financial …
Needham analyst Alan Carr was out today with a favorable report on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), after meeting with management for a corporate update and hosting a series of …
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) had a rough day today as shares fell 17%, after the antibiotic drug-maker announced that the FDA is requiring …
Needham’s healthcare analyst Alan Carr weighted in today on the pharmaceutical giant Gilead Sciences, Inc. (NASDAQ:GILD) and San Diego biopharmaceutical company Regulus Therapeutics Inc (NASDAQ:RGLS), after …
KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) shares skyrocketed more than 400% today after Turing Pharmaceuticals founder Martin Shkreli disclosed that he has purchased 1.2 million shares of the …
Analyst Alan Carr of Needham rates stocks in the biotechnology sector and is one of the top 25 analysts rated on TipRanks. Today, …
Needham’s healthcare analyst Alan Carr reiterated a Buy rating on shares of the liver disease company Intercept Pharmaceuticals Inc (NASDAQ:ICPT), with a price target of $500, …
In a research report released Friday, Needham’s healthcare analyst Alan Carr reiterated a Hold rating on shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), ahead of the company’s …
In a research report issued yesterday, Needham analyst Alan Carr reiterated a Buy rating on shares of Cempra Inc (NASDAQ:CEMP), with a price target …
